Orgenesis, a global biotech company working in cell and gene therapies (CGT) at the point of care, has announced the name change of the POC Services business from Morgenesis to Octomera, effective 30 June 2023, to reflect the growth and focus on providing advanced CGT services, facilities, and technologies.
Morgenesis was originally formed in 2022 to separate Orgenesis’ existing POCare Service and supply solutions from the other operations of Orgenesis. A new Octomera website and rebranding will be unveiled throughout the second half of 2023.
In addition, the Company announced that MM OS Holdings, an affiliate of Metalmark Capital Partners a leading private equity firm with extensive expertise in the healthcare sector, has deployed additional funds into Octomera. The capital from the MM investment is for the continued development of POCare Centers with a focus on expanding in the US market.
Octomera is focused on changing the paradigm of centralised cell and gene therapy (CGT) production to produce treatments in a decentralised point-of-care manner. Octomera provides the supply and development of decentralised services utilising the POCare Network of POCare Centers deployed independently and in partnership with academic institutes, hospitals, and industry partners. POCare Centers within the Network are harmonised and standardised by Octomera.
“The centralised biotech manufacturing model simply does not translate to efficient or cost-effective CGT production within the clinical development stage, and even less so for approved products,” said Vered Caplan, CEO of Orgenesis. “We have been working for years to reduce the complexity and cost of development and commercialisation of CGT products via decentralisation, and this rebranding as Octomera with the support of Metalmark marks a major milestone for both Orgenesis and Octomera. As a result of our efforts, investments, and foresight, we have now built a broad and growing POCare Network of centers across the US, Europe, and other regions, where our services can be rapidly scaled up to meet the growing demand across the industry.”
